Lyrica
Product Images NDC 42549-612

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 42549-612). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panelndc: 42549-612-30lyrica 75mg #30 Tablets (Lyrica 50 mg C V 42549)

Label for Lyrica C-V 50 mg capsules, 30 count, distributed by STAT Rx USA LLC and manufactured by Pfizer Inc. The label includes the NDC number 42549-660-30 and states each capsule contains 50 mg of Pregabalin. It also contains storage instructions and safety warnings.*

FDA Label Image

Principal Display Panel (Lyrica 75 mg C V 42549)

LYRICA C-V 75 mg capsules label showing a 90-count bottle. The label states each capsule contains pregabalin 75 mg. The product is distributed by STAT Rx USA LLC in Gainesville, GA, and lists Pfizer Inc. as the manufacturer. Includes NDC code 42549-612-90 and storage instructions.*

FDA Label Image

Figure Of The Cockcroft And Gault Equation (Lyrica 1)

A mathematical formula displaying the calculation for Creatinine Clearance (CLCr), involving age, weight, and serum creatinine values, with an adjustment factor of 0.85 for female patients.*

FDA Label Image

Figure 8: Patients Achieving Various Levels Of Pain Relief – Fibromyalgia Study F1 (Lyrica 10)

A line graph depicting the percent improvement in pain from baseline on the x-axis versus the percent of patients improved on the y-axis for LYRICA (pregabalin) at daily doses of 300 mg, 450 mg, 600 mg, and placebo. The graph shows separate lines for each dose and placebo, illustrating the varying degrees of patient improvement with increasing doses of pregabalin compared to placebo.*

FDA Label Image

Figure 9: Time To Loss Of Therapeutic Response, Fibromyalgia Study F2 (kaplan-meier Analysis) (Lyrica 11)

A Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without LTR over 180 days between Pregabalin and Placebo groups. The y-axis represents the estimated percentage of subjects without LTR from 0% to 100%, and the x-axis represents days from 0 to 180. The Pregabalin group shows a higher percentage of subjects without LTR over time compared to the Placebo group.*

FDA Label Image

The Chemical Structure Of Pregabalin. (Lyrica 2)

Chemical structure of the active ingredient for LYRICA, showing a molecular diagram with characteristic functional groups including an amino (NH2) and a carboxylic acid (CO2H) group attached to a branched carbon chain.*

FDA Label Image

Figure 1: Patients Achieving Various Levels Of Pain Relief – Study Dpn 1 (Lyrica 3)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares pregabalin at 25 mg, 100 mg, and 200 mg three times a day with placebo, illustrating treatment effects on pain improvement.*

FDA Label Image

Figure 2: Patients Achieving Various Levels Of Pain Relief – Study Dpn 2 (Lyrica 4)

A Kaplan-Meier plot showing the percent of patients improved over a range of percent improvement in pain from baseline. Two groups are compared: one receiving Pregabalin 100 mg three times a day and the other receiving placebo. The y-axis represents the percent of patients improved, and the x-axis shows the percent improvement in pain from baseline, with vertical lines marking specific improvement thresholds.*

FDA Label Image

Figure 3: Patients Achieving Various Levels Of Pain Relief – Study Phn 1 (Lyrica 5)

A line graph showing the percent of patients improved relative to percent improvement in pain from baseline. Lines represent different dosage groups of Pregabalin (75 mg, 150 mg, 300 mg twice a day) and a placebo group. The y-axis indicates the percent of patients improved, while the x-axis shows percent improvement in pain from baseline.*

FDA Label Image

Figure 4: Patients Achieving Various Levels Of Pain Relief – Study Phn 2 (Lyrica 6)

A line graph depicting the percent of patients improved relative to percent improvement in pain from baseline for LYRICA (pregabalin) at 100 mg and 200 mg three times a day compared to placebo. The x-axis displays percent improvement in pain, and the y-axis shows the percent of patients improved.*

FDA Label Image

Figure 5: Patients Achieving Various Levels Of Pain Relief – Study Phn 3 (Lyrica 7)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for LYRICA (pregabalin) at doses of 50 mg and 100 mg taken three times a day, compared to placebo. The graph depicts three lines illustrating patient improvement trends over varying levels of pain improvement.*

FDA Label Image

Figure 6. Responder Rate By Add-on Epilepsy Study (Lyrica 8)

A bar chart comparing responder rates (%) for two studies, Study E1 and Study E3. It shows response rates for placebo and various daily doses (50 mg, 100 mg, 150 mg for Study E1 and 8 mg, 100 mg for Study E3). The chart includes sample sizes (N) for each group, and indicates statistical significance with an asterisk for certain bars.*

FDA Label Image

Figure 7. Seizure Reduction By Dose (all Partial Onset Seizures) For Studies E1, E2, And E3 (Lyrica 9)

A line chart showing median percent seizure reduction from baseline versus dose in mg/day for LYRICA across four studies (E1BD, E2TID, E3BID, E3TID). The X-axis represents dose, and the Y-axis represents median percent seizure reduction. Data points include p-values indicating statistical significance at various doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.